First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland

Belzutifan is a new HIF-α inhibitor mainly used in two different indications: von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and pancreatic neuroendocrine tumours, as well as sporadic advanced pre-treated renal cell carcinoma. Although efficacy has been demonstrated i...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Current oncology (Toronto) Ročník 32; číslo 2; s. 64
Hlavní autoři:	Peres, Tobias, Aeppli, Stefanie, Fischer, Stefanie, Hundsberger, Thomas, Rothermundt, Christian
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland MDPI 26.01.2025 MDPI AG
Témata:	Adult Aged belzutifan Carcinoma, Renal Cell - drug therapy Case Report case series Female haemangioblastomas HIF-α inhibitor Humans Hypoxia-Inducible Factor 1, alpha Subunit - antagonists & inhibitors Indenes Kidney Neoplasms - drug therapy Male Middle Aged renal cell carcinoma Retrospective Studies Switzerland von Hippel-Lindau Disease - complications von Hippel-Lindau Disease - drug therapy von Hippel–Lindau syndrome Switzerland real-world renal cell carcinoma HIF-α inhibitor belzutifan case series von Hippel–Lindau syndrome haemangioblastomas
ISSN:	1718-7729, 1198-0052, 1718-7729
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!